NCT07626177 Association Between Screening Behaviors and Lung Cancer Spectrum
| NCT ID | NCT07626177 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fudan University |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,390 participants |
| Start Date | 2026-05-14 |
| Primary Completion | 2027-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,390 participants in total. It began in 2026-05-14 with a primary completion date of 2027-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to describe the clinical epidemiological characteristics and disease spectrum distribution of newly diagnosed primary lung cancer patients in a real-world setting. The main questions it aims to answer are: What is the current status of lung cancer epidemiology, including age, gender, smoking history, and pathological subtype distribution? How do different lung cancer screening behaviors (e.g., overscreening, underscreening, guideline-concordant, and precision screening) influence the capture rate of the "curative time window" (defined as adenocarcinoma in situ (AIS)/minimally invasive adenocarcinoma (MIA) or pure Ground-Glass Nodules (GGNs) stage)? What are the economic costs and cumulative radiation exposure associated with these different screening patterns? Researchers will compare these screening behavior groups to evaluate the efficacy of the "low-age, low-frequency" screening strategy in capturing early-stage lung cancer. Participants will be asked to: Provide their medical history and detailed records of pre-diagnosis lung cancer screening (including CT scan history). Allow researchers to collect and analyze their clinical, pathological, and radiological data from hospital records and medical databases. Complete a questionnaire regarding their screening history and health-related behaviors.
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed primary lung cancer within the past year (surgical or biopsy pathology). * Patients capable of clearly recalling or providing medical and physical examination history prior to diagnosis. Exclusion Criteria: * Recurrent lung cancer or metastatic lung tumors. * Severe lack of critical clinical data (e.g., inability to provide pathological type or stage). * Patients with cognitive impairment or severe mental illness who cannot cooperate with the questionnaire.
Frequently Asked Questions
Who can join the NCT07626177 clinical trial?
This trial is open to participants of all sexes, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07626177 currently recruiting?
Yes, NCT07626177 is actively recruiting participants. Visit ClinicalTrials.gov or contact Fudan University to inquire about joining.
Where is the NCT07626177 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07626177 clinical trial?
NCT07626177 is sponsored by Fudan University. The trial plans to enroll 5,390 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.